PARIS, March 15 (UPI) -- French firm Exonhit Therapeutics said Thursday it has identified a panel of genes that allows Alzheimer's disease to be diagnosed from a blood test.
The company said a panel of 60 biomarkers can clearly distinguish between men and women with and without the debilitating brain disease, based on a Mini Mental State Examination score of less than 20 and a Global Deterioration Scale score greater than or equal to 4.
Using a sample of 85 individuals -- 51 with Alzheimer's disease and 34 without symptoms of the disease -- the biomarkers correctly identified 78 percent of the AD cases and 82 percent of those free of the disorder, with an accuracy of 76 percent, the company said.
The same panel of genes also correctly classified as "non-AD" 81 percent of the individuals with neurological conditions such as depression, schizophrenia or bipolar disorders, Exonhit added.
The company said it would do a prospective clinical study to further test the biomarkers' accuracy.
The data from the initial study were presented at the 8th International Conference on Alzheimer and Parkinson diseases in Salzburg, Austria.